摘要
Abstract
Objective To observe the 3 year survival rate and clinical effect of late-stage hepatocellular carcinoma ( HCC ) patients treated with epirubicin. Methods 173 HCC patients who were not suitable for curable treatments were pro-spectively enrolled. Child Pugh ( Child ) class was A/B ( 102/71 ). The embolization procedure was performed as selectively cumulative survival rates were calculated. Kaplan-Meier 3 year survival curves were plotted for various subgroups, and differences between curves were analyzed using log rank test. Possible variables predictive of survival were analyzed by univariate a-nalysis using chi square test with Yates'correction. Results Overall survival rate at 1, 2, 3 years were 93. 6% , 83. 8% , 62.0% , with higher rates achieved in Child class A compared with Child class B patients ( 95.0% , 84. 2% , 61. 7% vs. 91. 5% , 70.0% , 43.7% ). Mean overall survival period was 43. 8 months ( ranged from 1.2 to 64. 8 months ). Cumulative survival was better for Child class A compared with Child class B patients ( P <0.05 ). For patients with dominant lesions ≤5 cm, 1, 2, 3 years survival rates were 100% , 95. 2% , 71. 4% for Child class A and 94. 1% , 88. 2% , 58. 8% for Child class B patients. Regarding TACE treatment, multivariate analysis identified the number of lesions ( P <0.05 ), lesion vascularity ( P < 0.01 ), initially achieved complete response ( P <0.01 ), and objective response ( P <0. 05 ) as significant and independent determinants of 3 year survival. Conclusion Epirubicin reveals high rates of 3 year survival for patients with late-stage HCC. Numbers of lesion, lesion vascularity, and local response were significant independent determinants of 3 year survival.关键词
肝癌,原发性,晚期/表柔比星/介入治疗/生存率Key words
Hepatocellular carcinoma, primary, late-stage/ Epirubicin/ Intervention therapy/ Survival rate
